As a global leader in pain research and management, we aim to create sustainable value for patients and their families, for our employees, customers and investors as well as the communities we operate in. We hold ourselves to high sustainability standards and the highest ethical business practices. Our performance against environmental, social and governance (ESG) criteria has been recognized in an external rating that placed Grünenthal in the top five percent of the global pharmaceuticals subindustry that inherently features higher ESG risk. The rating agency Sustainalytics attributed a medium ESG risk to Grünenthal and acknowledged the company’s strong management of its ESG risks.

To learn more, please see our Press Release.